A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | October 2001 |
| End Date: | June 2005 |
An Open-label Study of the Effect of Intermittent Xeloda in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer
This study will assess the efficacy and safety of intermittent oral Xeloda administration in
combination with irinotecan as a first-line treatment in patients with advanced and/or
metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the
target sample size is <100 individuals.
combination with irinotecan as a first-line treatment in patients with advanced and/or
metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months and the
target sample size is <100 individuals.
Inclusion Criteria:
- adult patients >=18 years of age;
- locally advanced and/or metastatic colorectal cancer;
- >=1 target lesion.
Exclusion Criteria:
- previous treatment with Xeloda or irinotecan;
- previous systemic therapy for metastatic disease;
- progressive disease during previous adjuvant therapy or within 6 months of
completion.
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials